We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.51B
AUM Growth
-$254M
Cap. Flow
-$15.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
28.7%
Holding
145
New
11
Increased
46
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$25.7M
2
AMGN icon
Amgen
AMGN
+$24.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.6M
4
QURE icon
uniQure
QURE
+$11.2M
5
CNC icon
Centene
CNC
+$11.2M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$77.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$47.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$31.8M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$23.8M
5
A icon
Agilent Technologies
A
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.82%
2 Consumer Staples 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEN icon
26
Penumbra
PEN
$12.8B
$32.6M 1.3%
242,500
+3,500
+1% +$541K
PTLA
27
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$28.2M 1.12%
1,050,000
+42,000
+4% +$1.18M
LKFT
28
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$26.7M 1.06%
175,000
+10,000
+6% +$1.64M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$29.3B
$26.6M 1.06%
330,500
+2,800
+0.9% +$222K
ONC
30
BeOne Medicines Ltd
ONC
$39.4B
$26.3M 1.05%
214,800
– –
RARE icon
31
Ultragenyx Pharmaceutical
RARE
$2.55B
$26M 1.04%
608,000
+28,000
+5% +$1.52M
SRPT icon
32
Sarepta Therapeutics
SRPT
$1.77B
$25.4M 1.01%
337,500
+12,500
+4% +$1.48M
ALDR
33
DELISTED
Alder Biopharmaceuticals
ALDR
$24.5M 0.98%
1,300,000
-262,300
-17% -$3M
BPMC
34
DELISTED
Blueprint Medicines
BPMC
$24.5M 0.98%
333,500
+26,000
+8% +$2.25M
AMGN icon
35
Amgen
AMGN
$222B
$24.4M 0.97%
+126,000
New +$24.2M
TMO icon
36
Thermo Fisher Scientific
TMO
$220B
$23.6M 0.94%
81,000
– –
MOH icon
37
Molina Healthcare
MOH
$10.3B
$23.5M 0.94%
214,500
+8,500
+4% +$1.1M
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$11.8B
$23.5M 0.94%
272,400
+15,500
+6% +$1.45M
INCY icon
39
Incyte
INCY
$24.4B
$23.2M 0.92%
312,300
– –
ALLK
40
DELISTED
Allakos
ALLK
$22.8M 0.91%
290,000
-114,000
-28% -$7.52M
NVTA
41
DELISTED
Invitae Corporation
NVTA
$21.7M 0.86%
1,125,000
– –
WST icon
42
West Pharmaceutical
WST
$24.9B
$21.6M 0.86%
152,500
+15,000
+11% +$2.07M
NVRO
43
DELISTED
NEVRO CORP.
NVRO
$20.8M 0.83%
242,500
+47,000
+24% +$3.56M
ARGX icon
44
argenx
ARGX
$54.1B
$20.7M 0.83%
181,700
– –
SGEN
45
DELISTED
Seagen Inc. Common Stock
SGEN
$20.7M 0.82%
242,000
– –
ASND icon
46
Ascendis Pharma A/S
ASND
$16.8B
$20.6M 0.82%
213,500
– –
ALGN icon
47
Align Technology
ALGN
$12.3B
$20.1M 0.8%
110,900
+5,900
+6% +$1.23M
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$20.1M 0.8%
257,500
+55,000
+27% +$5.16M
RARX
49
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$19.7M 0.79%
835,000
+31,000
+4% +$919K
EPZM
50
DELISTED
Epizyme, Inc
EPZM
$19.1M 0.76%
1,850,100
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Rock Springs Capital Management held 145 positions worth $2.51B, down 9.2% from $2.76B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2019 filing shows 11 new, 46 increased, 10 reduced and 7 closed positions. Its largest new stake was Amgen: 126,000 shares worth $24.4M. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $77.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

  • Rock Springs Capital Management's largest Q3 2019 buy was Amgen: 126,000 shares worth $24.4M.
  • Rock Springs Capital Management added most to AbbVie in Q3 2019, an estimated $25.7M increase.
  • Rock Springs Capital Management's biggest Q3 2019 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $77.4M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q3 2019, selling an estimated $47.6M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.51B portfolio in Q3 2019.
  • Rock Springs Capital Management opened 11 new positions and closed 7 in Q3 2019.
  • Rock Springs Capital Management's portfolio value fell 9.2% quarter-over-quarter to $2.51B.

Based on Rock Springs Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.